FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2912143218> ?p ?o ?g. }

• W2912143218 endingPage "901" @default.
• W2912143218 startingPage "888" @default.
• W2912143218 abstract "The benefits provided by disease-modifying treatments in multiple sclerosis have been demonstrated in clinical trials, but the extent to which they can be extrapolated to everyday care is less clear, as are the long-term benefits of treatment. The objective of this prospective observational cohort study performed in France was to evaluate the effectiveness and safety of glatiramer acetate in patients with relapsing-remitting multiple sclerosis over a 5-year period. All neurologists in France were invited to participate and enroll adult patients starting a first treatment with brand glatiramer acetate 20 mg. Given the observational nature of the study, no fixed study visits were imposed; consultations took place according to the investigator's normal practice. Occurrence of disease exacerbations and adverse events was documented and neurological disability evaluated with the EDSS at each consultation. Overall, 852 patients were analysable and 269 took glatiramer acetate continuously for 5 years. Median treatment duration was 3.4 years. Principal reasons for discontinuation were inadequate efficacy (38.9%), local tolerability (22.6%) and personal convenience (21.3%). Age, employment status, baseline EDSS score and number of previous exacerbations were variables associated with treatment persistence. The annualised exacerbation rate (5 years) was 0.41 [95% CI 0.39-0.44]; 316 patients (37.2%) remained exacerbation-free throughout. The risk of confirmed disability worsening (5 years) was 43.8% [95% CI 39.9-47.9%]. The most frequent adverse drug reactions were local injection site reactions (584 patients; 68.5%) and systemic immediate post-injection reactions (168 patients; 19.7%). Overall, these findings are consistent with those of previous clinical trials." @default.
• W2912143218 created "2019-02-21" @default.
• W2912143218 creator A5002445329 @default.
• W2912143218 creator A5041609738 @default.
• W2912143218 creator A5054561765 @default.
• W2912143218 creator A5057598570 @default.
• W2912143218 creator A5070805388 @default.
• W2912143218 creator A5077260404 @default.
• W2912143218 creator A5082292870 @default.
• W2912143218 creator A5082934897 @default.
• W2912143218 date "2019-02-07" @default.
• W2912143218 modified "2023-10-12" @default.
• W2912143218 title "Five-year outcome in the copaxone observatory: a nationwide cohort of patients with multiple sclerosis starting treatment with glatiramer acetate in France" @default.
• W2912143218 cites W1967253329 @default.
• W2912143218 cites W1968558564 @default.
• W2912143218 cites W2000897932 @default.
• W2912143218 cites W2005506388 @default.
• W2912143218 cites W2012040225 @default.
• W2912143218 cites W2031915800 @default.
• W2912143218 cites W2034710262 @default.
• W2912143218 cites W2036774081 @default.
• W2912143218 cites W2053121650 @default.
• W2912143218 cites W2061344099 @default.
• W2912143218 cites W2096015860 @default.
• W2912143218 cites W2099210971 @default.
• W2912143218 cites W2112165124 @default.
• W2912143218 cites W2114200907 @default.
• W2912143218 cites W2136809274 @default.
• W2912143218 cites W2138814556 @default.
• W2912143218 cites W2153466844 @default.
• W2912143218 cites W2160936210 @default.
• W2912143218 cites W2567400702 @default.
• W2912143218 cites W2751884637 @default.
• W2912143218 cites W2887090343 @default.
• W2912143218 doi "https://doi.org/10.1007/s00415-019-09211-5" @default.
• W2912143218 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6420902" @default.
• W2912143218 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30730008" @default.
• W2912143218 hasPublicationYear "2019" @default.
• W2912143218 type Work @default.
• W2912143218 sameAs 2912143218 @default.
• W2912143218 citedByCount "6" @default.
• W2912143218 countsByYear W29121432182020 @default.
• W2912143218 countsByYear W29121432182021 @default.
• W2912143218 countsByYear W29121432182022 @default.
• W2912143218 crossrefType "journal-article" @default.
• W2912143218 hasAuthorship W2912143218A5002445329 @default.
• W2912143218 hasAuthorship W2912143218A5041609738 @default.
• W2912143218 hasAuthorship W2912143218A5054561765 @default.
• W2912143218 hasAuthorship W2912143218A5057598570 @default.
• W2912143218 hasAuthorship W2912143218A5070805388 @default.
• W2912143218 hasAuthorship W2912143218A5077260404 @default.
• W2912143218 hasAuthorship W2912143218A5082292870 @default.
• W2912143218 hasAuthorship W2912143218A5082934897 @default.
• W2912143218 hasBestOaLocation W29121432181 @default.
• W2912143218 hasConcept C118552586 @default.
• W2912143218 hasConcept C126322002 @default.
• W2912143218 hasConcept C141071460 @default.
• W2912143218 hasConcept C16568411 @default.
• W2912143218 hasConcept C1862650 @default.
• W2912143218 hasConcept C187212893 @default.
• W2912143218 hasConcept C197934379 @default.
• W2912143218 hasConcept C201903717 @default.
• W2912143218 hasConcept C23131810 @default.
• W2912143218 hasConcept C2777014857 @default.
• W2912143218 hasConcept C2778375690 @default.
• W2912143218 hasConcept C2778577042 @default.
• W2912143218 hasConcept C2778715236 @default.
• W2912143218 hasConcept C2779134260 @default.
• W2912143218 hasConcept C2780640218 @default.
• W2912143218 hasConcept C2780892749 @default.
• W2912143218 hasConcept C71924100 @default.
• W2912143218 hasConcept C72563966 @default.
• W2912143218 hasConceptScore W2912143218C118552586 @default.
• W2912143218 hasConceptScore W2912143218C126322002 @default.
• W2912143218 hasConceptScore W2912143218C141071460 @default.
• W2912143218 hasConceptScore W2912143218C16568411 @default.
• W2912143218 hasConceptScore W2912143218C1862650 @default.
• W2912143218 hasConceptScore W2912143218C187212893 @default.
• W2912143218 hasConceptScore W2912143218C197934379 @default.
• W2912143218 hasConceptScore W2912143218C201903717 @default.
• W2912143218 hasConceptScore W2912143218C23131810 @default.
• W2912143218 hasConceptScore W2912143218C2777014857 @default.
• W2912143218 hasConceptScore W2912143218C2778375690 @default.
• W2912143218 hasConceptScore W2912143218C2778577042 @default.
• W2912143218 hasConceptScore W2912143218C2778715236 @default.
• W2912143218 hasConceptScore W2912143218C2779134260 @default.
• W2912143218 hasConceptScore W2912143218C2780640218 @default.
• W2912143218 hasConceptScore W2912143218C2780892749 @default.
• W2912143218 hasConceptScore W2912143218C71924100 @default.
• W2912143218 hasConceptScore W2912143218C72563966 @default.
• W2912143218 hasFunder F4320308970 @default.
• W2912143218 hasIssue "4" @default.
• W2912143218 hasLocation W29121432181 @default.
• W2912143218 hasLocation W29121432182 @default.
• W2912143218 hasLocation W29121432183 @default.
• W2912143218 hasLocation W29121432184 @default.
• W2912143218 hasLocation W29121432185 @default.
• W2912143218 hasOpenAccess W2912143218 @default.

• next